Humacyte is trading 6.6% higher at $0.48; biotech-sector strength is the likeliest context, but the cause is unconfirmed.
- XBI is up 2.18% during the regular session amid positive clinical and regulatory news across the industry; the broader market is nearly flat.
- No source found confirms a company-specific catalyst. Humacyte announced a new U.S. patent on October 28, extending protection for key Symvess manufacturing and handling technology into 2043.